Zimberelimab Biosimilar - Research Grade

Product Code: ICH5292

More Information

Species Reactivity: Human

Target: PD-1

Concentration: >1mg/ml

Isotype: Human IgG4 - lambda

Host: CHO Cells

product name H2: Zimberelimab Biosimilar - Research Grade

Antibodies against the same target: Anti-Mouse PD-1 (29F.1A12) In Vivo Antibody - Low Endotoxin (ICH1091), Anti-PD-1 (RMP1-14) (ICH1132), Anti-Mouse PD-1 (RMP1-14) Recombinant Antibody (ICH1182), Mouse Anti-Mouse PD-1 (29F.1A12) Recombinant Antibody (ICH1211), Anti-Mouse PD-1 (RMP1-30) In Vivo Antibody - Low Endotoxin (ICH1246), Anti-Human PD-1 (J110) In Vivo Antibody - Low Endotoxin (ICH1272), Nivolumab Biosimilar - Research Grade (ICH4009), Pembrolizumab Biosimilar - Research Grade (ICH4029), Sintilimab Biosimilar - Research Grade (ICH5001), Toripalimab Biosimilar - Research Grade (ICH5002), Camrelizumab Biosimilar - Research Grade (ICH5003), Tislelizumab Biosimilar - Research Grade (ICH5004), Penpulimab Biosimilar - Research Grade (ICH5112), Cemiplimab Biosimilar - Research Grade (ICH5161), Peresolimab Biosimilar - Research Grade (ICH5221), Acrixolimab Biosimilar - Research Grade (ICH5224), Adebrelimab Biosimilar - Research Grade (ICH5225), Enlonstobart Biosimilar - Research Grade (ICH5234), Ezabenlimab Biosimilar - Research Grade (ICH5238), Finotonlimab Biosimilar - Research Grade (ICH5241), Geptanolimab Biosimilar - Research Grade (ICH5243), Iparomlimab Biosimilar - Research Grade (ICH5248), Lipustobart Biosimilar - Research Grade (ICH5254), Nofazinlimab Biosimilar - Research Grade (ICH5262), Pimivalimab Biosimilar - Research Grade (ICH5266), Pradusinstobart Biosimilar - Research Grade (ICH5268), Pucotenlimab Biosimilar - Research Grade (ICH5269), Sugemalimab

Biosimilar - Research Grade (ICH5278), Retifanlimab Biosimilar - Research Grade (ICH5296), Dostarlimab Biosimilar - Research Grade (ICH5311), Balstilimab Biosimilar - Research Grade (ICH5369), Budigalimab Biosimilar - Research Grade (ICH5417), Cetrelimab Biosimilar - Research Grade (ICH5434), Gilvetmab Biosimilar - Research Grade (ICH5572), Lodapolimab Biosimilar - Research Grade (ICH5651), Pidilizumab Biosimilar - Research Grade (ICH5773), Prolgolimab Biosimilar - Research Grade (ICH5791), Rosnilimab Biosimilar - Research Grade (ICH5837), Rulonilimab Biosimilar - Research Grade (ICH5840), Sasanlimab Biosimilar - Research Grade (ICH5848), Serplulimab Biosimilar - Research Grade (ICH5855), Spartalizumab Biosimilar - Research Grade (ICH5881), Zeluvalimab Biosimilar - Research Grade (ICH6006)

Sequence: https://www.imgt.org/mAb-DB/

Buffer: ICH3002

UniProt: Q15116

Shipping Conditions: Blue ice

background: This product is a research-grade biosimilar of zimberelimab, an anti-PD-1 antibody. It is supplied as an unconjugated, non-therapeutic analog of the originator molecule and is intended strictly for research use only; it is not a clinical drug and is not for human or veterinary use. The antibody is built around the programmed cell death protein 1 (PD-1) target and is expressed as a human IgG4 (lambda) format, mirroring the isotype of the reference molecule. As with other IgG4-based checkpoint biosimilars, it recapitulates the antigen-binding properties of the originator while carrying the stabilized, low-effector-function characteristics associated with the IgG4 subclass. It is manufactured to research-grade endotoxin specifications (typically less than 1 EU/mg), and is available in bulk milligram-to-gram quantities suitable for in-vitro assays, screening cascades, and use as a reference or comparator reagent. It provides a cost-effective, consistently sourced alternative to therapeutic material for investigators studying PD-1 biology, checkpoint blockade mechanisms, and assay development, where a well-characterized anti-PD-1 binder is required. PD-1 (programmed cell death protein 1, gene PDCD1) is an inhibitory immune checkpoint receptor expressed on activated T cells, B cells, and myeloid cells. It is a type I transmembrane protein of the immunoglobulin superfamily bearing intracellular ITIM and ITSM motifs. Engagement by its ligands PD-L1 and PD-L2 recruits the phosphatase SHP-2, which dampens TCR and CD28 signaling, attenuating T-cell activation, proliferation, and cytokine production. This pathway maintains peripheral tolerance and limits

immunopathology, but tumors and chronic infections exploit it to drive T-cell exhaustion and immune evasion. Antibodies that block the PD-1/PD-L1 axis restore effector T-cell function and underpin a major class of cancer immunotherapies. PD-1 is therefore a central node in studies of tumor immunology, checkpoint blockade, and T-cell dysfunction.

Other names: Protein PD-1, hPD-1, Programmed cell death protein 1, PDCD1

Specificity: Detects human PD-1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks